4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Volume 36 Issue 4
Jul.  2022
Turn off MathJax
Article Contents
Abstract
References
Related Articles
Supplements
Fanyu Peng, Yizhi Ge, Rongrong Wang, Dingdong Hu, Xiang Cao, Yujie Zhang, Dan Zong, Xia He. Identifying nasopharyngeal carcinoma patients with metachronous metastasis sensitive to local treatment: a real-world study[J]. The Journal of Biomedical Research, 2022, 36(4): 221-230. DOI: 10.7555/JBR.36.20220060
Citation: Fanyu Peng, Yizhi Ge, Rongrong Wang, Dingdong Hu, Xiang Cao, Yujie Zhang, Dan Zong, Xia He. Identifying nasopharyngeal carcinoma patients with metachronous metastasis sensitive to local treatment: a real-world study[J]. The Journal of Biomedical Research, 2022, 36(4): 221-230. DOI: 10.7555/JBR.36.20220060
shu

Identifying nasopharyngeal carcinoma patients with metachronous metastasis sensitive to local treatment: a real-world study

  • 1.

    Department of Radiation Oncology, the Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu 210009, China

  • 2.

    Xuzhou Medical University, Xuzhou, Jiangsu 221004, China

More Information
  • Corresponding author:

    Xia He, Department of Radiation Oncology, Jiangsu Cancer Hospital, 42 Baiziting Road, Xuanwu District, Nanjing, Jiangsu 210009, China. Tel: +86-25-83284634, E-mail: hexiabm@163.com

  • Received Date: March 22, 2022
  • Revised Date: April 17, 2022
  • Accepted Date: April 27, 2022
  • Available Online: May 27, 2022
    Graphical Abstract
    • Abstract
  • It is difficult for physicians to identify patients with metastatic nasopharyngeal carcinoma (NPC) who are sensitive to local treatment of metastases. Here, we aimed to establish a prognostic model for survival and individualize treatments for patients with metastatic NPC. Data were collated from 240 NPC patients diagnosed with metachronous metastasis between 2006 and 2020 who received palliative chemotherapy with or without local treatment. Multivariable Cox regression was implemented to construct a nomogram which had a concordance index of 0.764 when predicting 1-, 3-, and 5-year overall survival (OS). We then classified patients according to risk, creating low- and high-risk groups using the nomogram. Differences in OS between the two groups were significant (P<0.001). In the low-risk group, the OS for patients who received local treatment was longer than those without (P=0.009). This novel nomogram shows good performance in classifying patients according to risk and may also be a promising tool for determining who responds best to local treatment. Further validation using external center data is warranted.
    • FullText(HTML)

  • CLC number: R739.6, Document code: A

    The authors reported no conflict of interests.

    △These authors contributed equally to this work.

    • References (29)
  • [1]
    Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394–424. doi: 10.3322/caac.21492
    [2]
    Mao Y, Tang L, Chen L, et al. Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy[J]. Chin J Cancer, 2016, 35(1): 103. doi: 10.1186/s40880-016-0167-2
    [3]
    Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience[J]. Int J Radiat Oncol Biol Phys, 2002, 53(1): 12–22. doi: 10.1016/S0360-3016(02)02724-4
    [4]
    Lai S, Li W, Chen L, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?[J]. Int J Radiat Oncol Biol Phys, 2011, 80(3): 661–668. doi: 10.1016/j.ijrobp.2010.03.024
    [5]
    Wu L, Liu Y, Jiang N, et al. Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: an analysis of 614 patients from a single center[J]. Oral Oncol, 2017, 69: 26–32. doi: 10.1016/j.oraloncology.2017.03.015
    [6]
    Yeo W, Leung TWT, Leung SF, et al. Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma[J]. Cancer Chemother Pharmacol, 1996, 38(5): 466–470. doi: 10.1007/s002800050512
    [7]
    Hong S, Zhang Y, Yu G, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 phase III study[J]. J Clin Oncol, 2021, 39(29): 3273–3282. doi: 10.1200/JCO.21.00396
    [8]
    Au E, Ang PT. A phase Ⅱ trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma[J]. Ann Oncol, 1994, 5(1): 87–89. doi: 10.1093/oxfordjournals.annonc.a058703
    [9]
    Weichselbaum R, Hellman S. Oligometastases revisited[J]. Nat Rev Clin Oncol, 2011, 8(6): 378–382. doi: 10.1038/nrclinonc.2011.44
    [10]
    You R, Liu Y, Huang P, et al. Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(9): 1345–1352. doi: 10.1001/jamaoncol.2020.1808
    [11]
    Huang J, Li Q, Zheng Y, et al. Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature[J]. BMC Cancer, 2014, 14: 818. doi: 10.1186/1471-2407-14-818
    [12]
    Jin Y, Cai Y, Cao Y, et al. Radiofrequency ablation combined with systemic chemotherapy in nasopharyngeal carcinoma liver metastases improves response to treatment and survival outcomes[J]. J Surg Oncol, 2012, 106(3): 322–326. doi: 10.1002/jso.23034
    [13]
    Ma J, Wen Z, Lin P, et al. The results and prognosis of different treatment modalities for solitary metastatic lung tumor from nasopharyngeal carcinoma: a retrospective study of 105 cases[J]. Chin J Cancer, 2010, 29(9): 787–795. doi: 10.5732/cjc.010.10098
    [14]
    Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document[J]. Radiother Oncol, 2020, 148: 157–166. doi: 10.1016/j.radonc.2020.04.003
    [15]
    Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation[J]. Lancet Oncol, 2020, 21(1): E18–E28. doi: 10.1016/S1470-2045(19)30718-1
    [16]
    Harrell FE Jr. Rms: Regression Modeling Strategies[EB/OL]. [2021-03-18]. https://github.com/harrelfe/rms.
    [17]
    Zhang J, Jin Z. nomogramFormula[EB/OL]. [2019-08-17]. https://github.com/yikeshu0611/nomogramFormula.
    [18]
    Du Z, Hao Y. nomogramEx: Extract Equations from a Nomogram[EB/OL]. [2017-08-29]. https://cran.r-project.org/web/packages/nomogramEx/index.html.
    [19]
    Zheng W, Zong J, Huang C, et al. Multimodality treatment may improve the survival rate of patients with metastatic nasopharyngeal carcinoma with good performance status[J]. PLoS One, 2016, 11(1): e0146771. doi: 10.1371/journal.pone.0146771
    [20]
    Tian Y, Zou W, Xiao W, et al. Oligometastases in AJCC stage IVc nasopharyngeal carcinoma: a subset with better overall survival[J]. Head Neck, 2016, 38(8): 1152–1157. doi: 10.1002/hed.24345
    [21]
    Zhao Z, Liu D, Wang Y, et al. Pulmonary metastasectomy in patients with lung metastases from nasopharyngeal carcinoma[J]. Ann Surg Oncol, 2021, 28(8): 4542–4550. doi: 10.1245/s10434-021-09597-5
    [22]
    Shen L, Dong J, Li S, et al. M1 stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma[J]. Oncologist, 2015, 20(3): 291–298. doi: 10.1634/theoncologist.2014-0206
    [23]
    Cao X, Han Y, He L, et al. Risk subset of the survival for nasopharyngeal carcinoma patients with bone metastases: who will benefit from combined treatment?[J]. Oral Oncol, 2011, 47(8): 747–752. doi: 10.1016/j.oraloncology.2011.05.010
    [24]
    Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial[J]. Lancet, 2019, 393(10185): 2051–2058. doi: 10.1016/S0140-6736(18)32487-5
    [25]
    Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study[J]. J Clin Oncol, 2019, 37(18): 1558–1565. doi: 10.1200/JCO.19.00201
    [26]
    Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial[J]. JAMA Oncol, 2018, 4(1): e173501. doi: 10.1001/jamaoncol.2017.3501
    [27]
    Ruers T, van Coevorden F, Punt CJA, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase Ⅱ trial[J]. J Natl Cancer Inst, 2017, 109(9): djx015. doi: 10.1093/jnci/djx015
    [28]
    Li W, Lv S, Liu G, et al. Development of a prognostic model to identify the suitable definitive radiation therapy candidates in de novo metastatic nasopharyngeal carcinoma: a real-world study[J]. Int J Radiat Oncol Biol Phys, 2021, 109(1): 120–130. doi: 10.1016/j.ijrobp.2020.08.045
    [29]
    Chee J, Liu X, Eu D, et al. Defining a cohort of oligometastatic nasopharyngeal carcinoma patients with improved clinical outcomes[J]. Head Neck, 2020, 42(5): 945–954. doi: 10.1002/hed.26061
    • Related Articles

  • Related Articles

    [1]Xiaolong Zheng, Wei Wang. Astrocyte transplantation for repairing the injured spinal cord[J]. The Journal of Biomedical Research, 2022, 36(5): 312-320. DOI: 10.7555/JBR.36.20220012
    [2]Marta Obara-Michlewska. The contribution of astrocytes to obesity-associated metabolic disturbances[J]. The Journal of Biomedical Research, 2022, 36(5): 299-311. DOI: 10.7555/JBR.36.20200020
    [3]Tiwari-Heckler Shilpa, Jiang Z. Gordon, Popov Yury, J. Mukamal Kenneth. Daily high-dose aspirin does not lower APRI in the Aspirin-Myocardial Infarction Study[J]. The Journal of Biomedical Research, 2020, 34(2): 139-142. DOI: 10.7555/JBR.33.20190041
    [4]Huan Liu, Shijiang Zhang, Yongfeng Shao, Xiaohu Lu, Weidong Gu, Buqing Ni, Qun Gu, Junjie Du. Biomechanical characterization of a novel ring connector for sutureless aortic anastomosis[J]. The Journal of Biomedical Research, 2018, 32(6): 454-460. DOI: 10.7555/JBR.31.20170011
    [5]Minbo Zang, Qiao Zhou, Yunfei Zhu, Mingxi Liu, Zuomin Zhou. Effects of chemotherapeutic agent bendamustine for nonhodgkin lymphoma on spermatogenesis in mice[J]. The Journal of Biomedical Research, 2018, 32(6): 442-453. DOI: 10.7555/JBR.31.20170023
    [6]Huanqiang Wang, Congying Yang, Siyuan Wang, Tian Wang, Jingling Han, Kai Wei, Fucun Liu, Jida Xu, Xianzhen Peng, Jianming Wang. Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer[J]. The Journal of Biomedical Research, 2018, 32(6): 424-433. DOI: 10.7555/JBR.32.20170065
    [7]Fengzhen Wang, Mingwan Zhang, Dongsheng Zhang, Yuan Huang, Li Chen, Sunmin Jiang, Kun Shi, Rui Li. Preparation, optimization, and characterization of chitosancoated solid lipid nanoparticles for ocular drug delivery[J]. The Journal of Biomedical Research, 2018, 32(6): 411-423. DOI: 10.7555/JBR.32.20160170
    [8]Anna Karolina Zuk, Xuesong Wen, Stephen Dilworth, Dong Li, Lucy Ghali. Modeling and validating three dimensional human normal cervix and cervical cancer tissues in vitro[J]. The Journal of Biomedical Research, 2017, 31(3): 240-247. DOI: 10.7555/JBR.31.20160150
    [9]Shengfa Ni, Lingxiang Liu, Yongqian Shu. Sequential transcatheter arterial chemoembolization, three-dimensional conformal radiotherapy, and high-intensity focused ultrasound treatment for unresectable hepatocellular carcinoma patients[J]. The Journal of Biomedical Research, 2012, 26(4): 260-267. DOI: 10.7555/JBR.26.20120016
    [10]Amit Kumar Sharma, Rajeev Kumar Tiwari, Mulayam Singh Gaur. Three dimensional structure prediction and proton nuclear magnetic resonance analysis of toxic pesticides in human blood plasma[J]. The Journal of Biomedical Research, 2012, 26(3): 170-184. DOI: 10.7555/JBR.26.20110132
    • Supplements (1)

  • Other Related Supplements

  • Cited by

    Periodical cited type(1)

    1. Atabati H, Raoofi A, Amini A, et al. Evaluating HER2 Gene Amplification Using Chromogenic In Situ Hybridization (CISH) Method In Comparison To Immunohistochemistry Method in Breast Carcinoma. Open Access Maced J Med Sci, 2018, 6(11): 1977-1981. DOI:10.3889/oamjms.2018.455

    Other cited types(0)

Catalog

    Figures(5)  /  Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1513) PDF downloads (243) Cited by(1)
    Related

    ©2023 by the Editorial Department of the Journals of Nanjing Medical University. All rights reserved.   苏ICP备05071376号-5

    Supported by: Beijing Renhe Information Technology Co., Ltd. E-mail: info@rhhz.net  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return